Healthcare3 min reading time
This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials
The Next Web
Read the full article
Qureight, a Cambridge startup founded by doctors, raised $20m to develop a general 3D AI model of the chest to accelerate disease-specific imaging models for lung and heart clinical trials, reducing trial imaging decision times significantly. The company aims to expand its models to various chest diseases and already works with major pharma firms, planning to grow its team and maintain its London base amid strong investor interest.
